Drug profile · INN
belantamab mafodotin-blmf
BLENREP
belantamab mafodotin-blmf (BLENREP) is a tubulin inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — belantamab mafodotin-blmf
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
belantamab mafodotin-blmf (BLENREP) is a tubulin inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Tubulin inhibitor
Primary target: Tubulin
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Recent coverage
GSK’s Blenrep returns to the US market after FDA approves resubmission
The FDA has approved GSK’s Blenrep in combination with bortezomib and dexamethasone, clearing the drug’s return to the US market. The move ends a withdrawal that followed a failed confirmatory study and resets the catalyst timeline for investors and BD teams.
GSK Blenrep wins FDA approval in relapsed multiple myeloma
GSK’s Blenrep has returned to the U.S. market after the FDA approved it in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma. The catalyst matters for BD teams and investors because it reverses a prior withdrawal and resets the drug’s U.S. label and commercial outlook.
Congress & event coverage
- Presentation2026 U.S.-Japan Healthcare
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is belantamab mafodotin-blmf?
belantamab mafodotin-blmf (BLENREP) is a tubulin inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for belantamab mafodotin-blmf?
BLENREP is a marketed brand name for belantamab mafodotin-blmf. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of belantamab mafodotin-blmf?
belantamab mafodotin-blmf has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.